Boji Medical completes cancellation of stock options

Guangzhou Boji Medical & Biotechnological (SZSE:300404) announced the completion of the cancellation of certain stock options initially granted under its 2022 equity incentive plan. The cancellation involves 13,440 stock options previously granted to one departing employee who no longer meets the incentive plan's eligibility requirements due to resignation. The decision was approved at the company's board and supervisory meetings held on April 24, 2025. The cancellation process has been verified and completed through China Securities Depository and Clearing Corporation Limited Shenzhen Branch. Boji Medical clarifies that the cancellation of these unexercised options will not impact the company's share capital.